Loading
Yanuki
KEYWORD TOPIC
Minerva Neurosciences Secures $200 Million to Advance Schizophrenia Treatment | Minerva Neurosciences Secures Up to $200 Million Financing | Minerva Neurosciences Secures $200 Million to Advance Schizophrenia Treatment | Minerva Neurosciences Secures Up to $200 Million Financing

News / Biotech

Minerva Neurosciences Secures $200 Million to Advance Schizophrenia Treatment

Minerva Neurosciences (NERV) has secured up to $200 million in funding through a private placement to advance the development of roluperidone, a treatment for negative symptoms of schizophrenia. This significant financial boost aims to supp...

Why Is Minerva Neurosciences Stock (NERV) Up 165% Today?
Minerva Neurosciences Secures $200 Million to Advance Schizophrenia Treatment Image via TipRanks
TOPIC nerv stock

News / Finance

Minerva Neurosciences Secures Up to $200 Million Financing

Minerva Neurosciences (NERV) has announced a private placement, securing up to $200 million to further the development of roluperidone, a treatment for schizophrenia. This funding aims to support a Phase 3 confirmatory trial and resubmissio...

Minerva Neurosciences (NASDAQ: NERV) secures up to $200M for roluperidone Phase 3